ICON Management

Management criteria checks 3/4

ICON's CEO is Steve Cutler, appointed in Mar 2017, has a tenure of 7.08 years. total yearly compensation is $10.03M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 0.045% of the company’s shares, worth €10.57M. The average tenure of the management team and the board of directors is 12.2 years and 7 years respectively.

Key information

Steve Cutler

Chief executive officer

US$10.0m

Total compensation

CEO salary percentage	11.6%
CEO tenure	7.1yrs
CEO ownership	0.04%
Management average tenure	12.2yrs
Board average tenure	7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Cutler's remuneration changed compared to ICON's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$683m
Dec 31 2023	n/a	n/a	US$612m
Sep 30 2023	n/a	n/a	US$513m
Jun 30 2023	n/a	n/a	US$510m
Mar 31 2023	n/a	n/a	US$510m
Dec 31 2022	US$10m	US$1m	US$505m
Sep 30 2022	n/a	n/a	US$464m
Jun 30 2022	n/a	n/a	US$210m
Mar 31 2022	n/a	n/a	US$168m
Dec 31 2021	US$10m	US$1m	US$153m
Sep 30 2021	n/a	n/a	US$178m
Jun 30 2021	n/a	n/a	US$364m
Mar 31 2021	n/a	n/a	US$338m
Dec 31 2020	US$8m	US$1m	US$328m
Sep 30 2020	n/a	n/a	US$322m
Jun 30 2020	n/a	n/a	US$324m
Mar 31 2020	n/a	n/a	US$368m
Dec 31 2019	US$8m	US$1m	US$369m
Sep 30 2019	n/a	n/a	US$362m
Jun 30 2019	n/a	n/a	US$353m
Mar 31 2019	n/a	n/a	US$333m
Dec 31 2018	US$8m	US$1m	US$323m
Sep 30 2018	n/a	n/a	US$306m
Jun 30 2018	n/a	n/a	US$295m
Mar 31 2018	n/a	n/a	US$288m
Dec 31 2017	US$7m	US$1m	US$281m

Compensation vs Market: Steve's total compensation ($USD10.03M) is above average for companies of similar size in the German market ($USD5.58M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve Cutler (63 yo)

7.1yrs

Tenure

US$10,028,000

Compensation

Dr. Steven A. Cutler, also known as Steve, Ph D., MBA, serves as Chairman of Association of Clinical Research Organizations since January 01, 2021. He has been the Chief Executive Officer of ICON Public Li...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Climax	Founder & Independent Non-Executive Director	no data	US$290.00k	0.54% $ 128.1m
Brendan Brennan	Chief Financial Officer	12.2yrs	US$2.06m	0.027% $ 6.3m
Steven Cutler	CEO & Director	7.1yrs	US$10.03m	0.045% $ 10.6m
Jonathan Curtain	Senior Vice President of Corporate & Commercial Finance	no data	no data	no data
Thomas O'Leary	Chief Information Officer	no data	no data	no data
Diarmaid Cunningham	Chief Administrative Officer	14.4yrs	no data	no data
Niamh Murphy	Director of Corporate Communications	no data	no data	no data
David Green	Vice President of Marketing	no data	no data	no data
Joe Cronin	Chief Human Resources Officer	7.8yrs	no data	no data
Simon Holmes	President of Corporate Investments & Partnerships	1.4yrs	no data	no data
Gary Curtis	Senior Vice President of Global Clinical Pharmacology	15yrs	no data	no data
Peter Schueler	Senior Vice President of Drug Development Services - CNS	17.3yrs	no data	no data

12.2yrs

Average Tenure

52yo

Average Age

Experienced Management: IJF's management team is seasoned and experienced (12.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
John Climax	Founder & Independent Non-Executive Director	14.3yrs	US$290.00k	0.54% $ 128.1m
Steven Cutler	CEO & Director	8.4yrs	US$10.03m	0.045% $ 10.6m
Linda Grais	Independent Director	2.8yrs	US$231.00k	0.0054% $ 1.3m
Eugene McCague	Independent Non-Executive Director	6.5yrs	US$323.00k	0.0026% $ 605.4k
Ciaran Murray	Independent Non-Executive Chairman of the Board	12.5yrs	US$630.00k	0.023% $ 5.5m
Ronan Murphy	Lead Independent Director	7.5yrs	US$359.00k	0.0026% $ 605.4k
Joan Garahy	Independent Non-Executive Director	6.4yrs	US$323.00k	0.0026% $ 605.4k
Julie O'Neill	Independent Non-Executive Director	4.8yrs	US$310.00k	0.0023% $ 551.3k

7.0yrs

Average Tenure

63.5yo

Average Age

Experienced Board: IJF's board of directors are considered experienced (7 years average tenure).

ICON Management

Management criteria checks 3/4

Key information

Recent management updates

Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024

ICON Public Limited Company, Annual General Meeting, Jul 25, 2023

Insufficient new directors

ICON Public Limited Company, Annual General Meeting, Jul 26, 2022

Recent updates

Now 21% undervalued

First quarter 2024 earnings released: EPS: US$2.27 (vs US$1.43 in 1Q 2023)

Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024

ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released: EPS: US$7.46 (vs US$6.20 in FY 2022)

ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024

Now 21% undervalued

ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024

ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024

Third quarter 2023 earnings released: EPS: US$1.99 (vs US$1.96 in 3Q 2022)

ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.

ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023

ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution

ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial

Second quarter 2023 earnings released: EPS: US$1.41 (vs US$1.42 in 2Q 2022)

ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023

ICON Public Limited Company, Annual General Meeting, Jul 25, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$1.43 (vs US$1.37 in 1Q 2022)

Now 22% undervalued

Full year 2022 earnings released: EPS: US$6.20 (vs US$2.28 in FY 2021)

ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023

Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$1.96 (vs US$1.17 loss in 3Q 2021)

ICON Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$1.40 in 2Q 2021)

Icon Public Limited Company Revises Earnings Guidance for the Year 2022

ICON Public Limited Company to Report Q2, 2022 Results on Jul 27, 2022

ICON Public Limited Company, Annual General Meeting, Jul 26, 2022

First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.84 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $100 million worth of its shares.

Now 21% undervalued after recent price drop

Now 21% undervalued

ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2021

Third quarter 2021 earnings released: US$1.17 loss per share (vs US$1.74 profit in 3Q 2020)

Investor sentiment improved over the past week

ICON Public Limited Company Provides Earnings Guidance for the Year 2021

Second quarter 2021 earnings released: EPS US$1.40 (vs US$0.91 in 2Q 2020)

ICON Public Limited Company (NasdaqGS:ICLR) completed the acquisition of PRA Health Sciences, Inc. (NasdaqGS:PRAH).

First quarter 2021 earnings released: EPS US$1.84 (vs US$1.63 in 1Q 2020)

ICON Public Limited Company Raises Earnings Guidance for the Full Year 2021

New 90-day low: €151

ICON Public Limited Company (NasdaqGS:ICLR) entered into an agreement to acquire PRA Health Sciences, Inc. (NasdaqGS:PRAH) for $10.8 billion.

Full year 2020 earnings released: EPS US$6.29 (vs US$6.85 in FY 2019)

Revenue beats expectations

ICON Public Limited Company Announces the Release of Two New Digital Solutions Supporting Clinical Research Sites and Sponsors

New 90-day high: €176

ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

New 90-day high: €169

ICON Public Limited Company (NasdaqGS:ICLR) acquired remaining stake in MeDiNova Limited.

New 90-day high - €168

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age